Opocrin S.p.A.

Since 1964 Opocrin has been involved in research, production and marketing of active pharmaceutical ingredients derived from animal organs and tissues. Lifesaving drugs such as heparin, low molecular-weight heparin, sulodexide, and pulmonary surfactant are the active ingredients of greatest interest to the company. Opocrin has recently broadened its range of offerings with the production of iron complexes such as sodium gluconate, ferric sodium saccharate and ferric protein.

With its established position in the European, Chinese and North and South American markets, Opocrin is ready to take on the challenge of the future and has set itself new goals in the fields of gynaecology and ophthalmology. The work of the highly integrated Opocrin R&D team has led to international patents and publications in pre-eminent industry journals, thus contributing to its own scientific prestige and that of the company as a whole.

The Saetti Bianchini family has recently acquired the majority shareholding in the company. Since 2007 the group has been led by Chairman Enrico Boldrini and Vice Chairman and Managing Director Carlo Saetti.